Global, regional, and national incidence of six major immune-mediated inflammatory diseases: findings from the global burden of disease study 2019

Background The causes for immune-mediated inflammatory diseases (IMIDs) are diverse and the incidence trends of IMIDs from specific causes are rarely studied. The study aims to investigate the pattern and trend of IMIDs from 1990 to 2019. Methods We collected detailed information on six major causes of IMIDs, including asthma, inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, psoriasis, and atopic dermatitis, between 1990 and 2019, derived from the Global Burden of Disease study in 2019. The average annual percent change (AAPC) in number of incidents and age standardized incidence rate (ASR) on IMIDs, by sex, age, region, and causes, were calculated to quantify the temporal trends. Findings In 2019, rheumatoid arthritis, atopic dermatitis, asthma, multiple sclerosis, psoriasis, inflammatory bowel disease accounted 1.59%, 36.17%, 54.71%, 0.09%, 6.84%, 0.60% of overall new IMIDs cases, respectively. The ASR of IMIDs showed substantial regional and global variation with the highest in High SDI region, High-income North America, and United States of America. Throughout human lifespan, the age distribution of incident cases from six IMIDs was quite different. Globally, incident cases of IMIDs increased with an AAPC of 0.68 and the ASR decreased with an AAPC of −0.34 from 1990 to 2019. The incident cases increased across six IMIDs, the ASR of rheumatoid arthritis increased (0.21, 95% CI 0.18, 0.25), while the ASR of asthma (AAPC = −0.41), inflammatory bowel disease (AAPC = −0.72), multiple sclerosis (AAPC = −0.26), psoriasis (AAPC = −0.77), and atopic dermatitis (AAPC = −0.15) decreased. The ASR of overall and six individual IMID increased with SDI at regional and global level. Countries with higher ASR in 1990 experienced a more rapid decrease in ASR. Interpretation The incidence patterns of IMIDs varied considerably across the world. Innovative prevention and integrative management strategy are urgently needed to mitigate the increasing ASR of rheumatoid arthritis and upsurging new cases of other five IMIDs, respectively. Funding The Global Burden of Disease Study is funded by the Bill and Melinda Gates Foundation. The project funded by Scientific Research Fund of Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital (2022QN38)

Prosopis pods as human food, with special reference to Kenya#

Several legume tree and shrub species of the genus Prosopis from South and Central America have been distributed around the dry regions of the world over the past 200 years. The first documented introduction of Prosopis in Kenya was in 1973, since when it has spread widely, adversely affecting natural habitats, rangelands and cultivated areas. P. juliflora is the most common naturalised species in Kenya, but P. pallida also occurs. In contrast to their undesirable effects as invasive weeds, many Prosopis species are valuable multipurpose resources in their native range, providing timber, firewood, livestockfeed, human food, shade, shelter and soil improvement. The pods, which are high in sugars, carbohydrates and protein, have been a historic source of food for human populations in North and South America providing flour and other edible products. However, this indigenous knowledge has not followed the Prosopis trees and the fruit are unused or provide only fodder for livestock in most of Africa and Asia. Although Prosopis will not easily be eradicated in Kenya, a degree ofcontrol may be achieved through intensive utilisation of tree products and by improved management. In 2005, a project waslaunched in Kenya to develop income-generating activities using Prosopis. A workshop in 2006 explored the possibility ofproducing locally-acceptable food from Prosopis flour. Taste tests and feedback on the different recipes indicated that all of the food made with 20% Prosopis flour had a pleasant taste. Preliminary analyses of Prosopis flour samples from Kenya indicate good nutritional properties, but also the presence of aflatoxins and Ochratoxin A. Further study is required to determine toxin levels in freshly harvested pods, and in pods and flour after various periods of storage, and to developappropriate harvesting and storage methods to maximise nutritional benefit and minimise risk to human health

Optimized Nanostructured Lipid Carriers Integrated into in situ Nasal Gel for Enhancing Brain Delivery of Flibanserin [Retraction]

Fahmy UA, Ahmed OAA, Badr-Eldin SM, et al. Int J Nanomedicine. 2020;15:5253-5264. The Editor and Publisher of International Journal of Nanomedicine are retracting the above published article. An investigation by the Publisher, found overlap in images from Figure 6 of the published article above and the images from Figure 6 of the following published article: Ahmed OAA, Fahmy UA, Badr-Eldin SM, et al. Application of Nanopharmaceutics for Flibanserin Brain Delivery Augmentation Via the Nasal Route. Nanomaterials. 2020; 10(7):1270 (https://doi.org/10.3390/nano10071270). Specifically, this included: From the published article above, Figure 6B, plain in situ gel group, and 6D, optimized FLB-NLC in situ gel group, are the same images as Figure 6D, rats treated with optimized FLB-TRF hydrogel (gp4) and 6C, rats treated with raw FLB loaded in hydrogel (gp3), respectively, from Ahmed et al, 2020. Furthermore, the images in Figure 6 of the published article above are derived from the same image but used to describe different results. Specifically, this included: From the published article above, Figure 6A, Control untreated group; 6B, plain in situ gel group; 6C, raw FLB loaded in situ gel group and 6D, optimized FLB-NLC in situ gel group, are all derived from the same image but used to describe different results. The authors cooperated with the investigation and provided data and associated documents concerning the histopathological experiments from the reported study. However, the Editor and Publisher determined that the evidence provided did not establish sufficient justification for the duplication. Therefore, the Editor and Publisher are retracting the article. The authors have agreed to retract the article and have informed the Publisher that the first author, Usama A Fahmy, takes responsibility for the error which occurred. We have been informed in our decision-making by our policy on publishing ethics and integrity and the COPE guidelines. The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”